The “stealth omicron” subvariant is now the dominant strain in the U.S., according to the Centers for Disease Control and Prevention.
BA.2 made up 54.9% of all new COVID-19 infections last week in the U.S., according to the CDC. That’s up from 39% the previous week.
Though experts have been monitoring the subvariant, several have said that they do not foresee it causing another surge in cases.
“We will have a wave. The only question is how big it will be,” tweeted Dr. Eric Topol, director of the Scripps Research Translational Institute in La Jolla.
Added Scripps microbiologist Kristian Andersen: “I expect we’ll see a wave — I don’t know if it’ll be a surge.”
The hardest hit region continues to be the Northeast, where stealth omicron is behind more than 70% of new cases.
Read More
In the Southwestern U.S. — which includes California, Arizona, Nevada and Hawaii — BA.2 made up an estimated 60.5% of coronavirus samples over the same week. The week before, the share was 45%.
The South and Mountain West are seeing the fewest cases in the US. BA.2 is causing slightly more than one-third of infections in those regions.
Experts have repeatedly said that BA.2 — a genetically distinct branch of the omicron variant (BA.1) — will eventually become the dominant strain in the United States.
BA.2 is believed to be 30% to 60% more contagious than the first dominant omicron subvariant.
According to a new study — not yet peer-reviewed and posted online Sunday — from Sweden that analyzed swab samples, the levels of coronavirus found in noses with BA.2 were nearly twice as high as in noses with BA.1.
“Higher viral load in the upper pharynx may at least partially explain why omicron BA.2 is more contagious than the BA.1 lineage,” the study said.
There are eight states that have shown at least a 10% increase in coronavirus cases in the last two weeks, according to a Sunday tweet from Dr. Topol. And the national test positivity rate — the percentage of which coronavirus tests analyzed in labs come back positive — is now around 3%, up from 2.1% in March, he added.
Stephanie Silvera, an infectious disease expert and professor at Montclair State University, said that gastrointestinal symptoms seemed to have returned with BA.2, whereas they had disappeared with the delta strain.
“One of the early symptoms of the original strain of COVID, which was not recognized at the time were these gastrointestinal issues,” she said. “And then they seem to go away with delta and with the BA.1 omicron. But with BA.2, those symptoms do seem to be back. So when people are trying to determine, ‘Is this a cold, or is this COVID?’ — it’s important to know what the common symptoms are. So I think that’s something that we need to be aware of.”
So far, a BA.2-fueled surge has yet to materialize nationally. However, there are some indications that the country’s progress in shaking off the winter’s omicron wave has slowed.
The rolling average of newly reported coronavirus cases has hovered between 27,000 and 28,000 a day for the better part of two weeks, according to the CDC. That’s still more than double the pre-delta surge lows of fewer than 10,000 cases a day nearly one year ago.
The U.S. Food and Drug Administration on Tuesday authorized a second booster dose for adults age 50 and older — which would be the fourth dose for those originally vaccinated with the Pfizer or Moderna vaccinations, and a third dose who originally got the Johnson & Johnson vaccine. The issue now goes to the Centers for Disease Control and Prevention to weigh in.
It would be more likely that an area would avoid a new springtime surge if more people got their shots, said Dr. Robert Kim-Farley, a UCLA epidemiologist and infectious disease expert. “The fourth dose will be especially helpful for those who are at higher risk of severe disease or death,” Kim-Farley said.
Los Angeles Times and CNN contributed.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.